{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:36:42Z","timestamp":1791121002127,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1034,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>We aimed to evaluate the effects of droxidopa (an oral synthetic precursor of norepinephrine) on the hemodynamic and renal alterations of portal hypertensive rats. Sham, portal vein-ligated (PVL), and 4-week biliary duct-ligated (BDL) rats received a single oral dose of droxidopa (25-50 mg\/kg) or vehicle and hemodynamic parameters were monitored for 2 hours. Two groups of BDL and cirrhotic rats induced by carbon tetrachloride (CCl4) were treated for 5 days with droxidopa (15 mg\/kg, twice daily, orally); hemodynamic parameters and blood and urinary parameters were assessed. The droxidopa effect on the Rho kinase (RhoK) \/ protein kinase B (AKT) \/ endothelial nitric oxide synthase (eNOS) pathways was analyzed by western blot in superior mesenteric artery (SMA). The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow. Two-hour diuresis greatly increased. Carbidopa (DOPA decarboxylase inhibitor) blunted all effects of droxidopa. Chronic droxidopa therapy in BDL rats produced the same beneficial hemodynamic effects observed in the acute study, did not alter liver function parameters, and caused a 50% increase in 24-hour diuresis volume (7.4 \u00b1 0.9 mL\/100g in BDL vehicle versus 11.8 \u00b1 2.5 mL\/100g in BDL droxidopa;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.01). Droxidopa-treated rats also showed a decreased ratio of p-eNOS\/eNOS and p-AKT\/AKT and increased activity of RhoK in SMA. The same chronic treatment in CCl4 rats caused similar hemodynamic effects and produced significant increases in diuresis volume and 24-hour natriuresis (0.08 \u00b1 0.02 mmol\/100g in CCl4 vehicle versus 0.23 \u00b1 0.03 mmol\/100g in CCl4 droxidopa;<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.014).<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion :<\/jats:title>\n            <jats:p>\n                                 <jats:bold>Droxidopa might be an effective therapeutic agent for hemodynamic and renal alterations of liver cirrhosis and should be tested in cirrhosis patients.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.25845","type":"journal-article","created":{"date-parts":[[2012,5,18]],"date-time":"2012-05-18T17:10:38Z","timestamp":1337361038000},"page":"1849-1860","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats"],"prefix":"10.1097","volume":"56","author":[{"given":"Mar","family":"Coll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarai","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Raurell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahia","family":"Ezkurdia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Brull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Guardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Martell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Genesc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-29-20241202","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1055\/s-2008-1040323","article-title":"Pathogenesis and treatment of hepatorenal syndrome.","volume":"28","author":"Arroyo","year":"2008","journal-title":"Semin Liver Dis"},{"key":"R2-29-20241202","doi-asserted-by":"crossref","first-page":"12791290","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis.","volume":"361","author":"Gines","year":"2009","journal-title":"N Engl J Med"},{"key":"R4-29-20241202","doi-asserted-by":"crossref","first-page":"S121S131","DOI":"10.1002\/hep.20993","article-title":"The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule.","volume":"43","author":"Iwakiri","year":"2006","journal-title":"Hepatology"},{"key":"R5-29-20241202","first-page":"208220","article-title":"Physiopathology of splanchnic vasodilation in portal hypertension.","volume":"2","author":"Martell","year":"201","journal-title":"World J Hepatol"},{"key":"R6-29-20241202","first-page":"2836","article-title":"Current concepts on the pathophysiology of portal hypertension.","volume":"6","author":"RodriguezVilarrupla","year":"2007","journal-title":"Ann Hepatol"},{"key":"R7-29-20241202","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1016\/j.jhep.2008.03.015","article-title":"Downregulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension.","volume":"49","author":"Coll","year":"2008","journal-title":"J Hepatol"},{"key":"R8-29-20241202","doi-asserted-by":"crossref","first-page":"593602","DOI":"10.1111\/j.1478-3231.2009.02176.x","article-title":"Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension.","volume":"30","author":"Coll","year":"2010","journal-title":"Liver International"},{"key":"R9-29-20241202","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1055\/s-2008-1040320","article-title":"The management of ascites and hyponatremia in cirrhosis.","volume":"28","author":"Gines","year":"2008","journal-title":"Semin Liver Dis"},{"key":"R10-29-20241202","doi-asserted-by":"crossref","first-page":"11351145","DOI":"10.1016\/j.jhep.2010.08.001","article-title":"Renal and circulatory dysfunction in cirrhosis: current management and future perspectives.","volume":"53","author":"Sola","year":"2010","journal-title":"J Hepatol"},{"key":"R11-29-20241202","doi-asserted-by":"crossref","first-page":"189203","DOI":"10.1111\/j.1527-3466.2006.00189.x","article-title":"LDihydroxyphenylserine (LDOPS): a norepinephrine prodrug.","volume":"24","author":"Goldstein","year":"2006","journal-title":"Cardiovasc Drug Rev"},{"issue":"Suppl 1","key":"R12-29-20241202","first-page":"1924","article-title":"Ldihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.","volume":"18","author":"Kaufmann","year":"2008","journal-title":"Clin Auton Res"},{"issue":"Suppl 1","key":"R13-29-20241202","first-page":"2529","article-title":"Ldihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.","volume":"18","author":"Mathias","year":"2008","journal-title":"Clin Auton Res"},{"key":"R14-29-20241202","doi-asserted-by":"crossref","first-page":"297308","DOI":"10.1007\/s11011-006-9036-z","article-title":"Functional abnormalities of the motor tract in the rat after portocaval anastomosis and after carbon tetrachloride induction of cirrhosis.","volume":"21","author":"Oria","year":"2006","journal-title":"Metab Brain Dis"},{"key":"R15-29-20241202","doi-asserted-by":"crossref","first-page":"13001314","DOI":"10.1136\/gut.2007.144584","article-title":"Mechanisms of extrahepatic vasodilation in portal hypertension.","volume":"57","author":"Hennenberg","year":"2008","journal-title":"Gut"},{"key":"R16-29-20241202","doi-asserted-by":"crossref","first-page":"772777","DOI":"10.1111\/j.2042-7158.1981.tb13929.x","article-title":"Pressor effect of Lthreo3,4dihydroxyphenylserine in rats.","volume":"33","author":"Araki","year":"1981","journal-title":"J Pharm Pharmacol"},{"key":"R17-29-20241202","doi-asserted-by":"crossref","first-page":"533534","DOI":"10.1111\/j.2042-7158.1986.tb04631.x","article-title":"Diuretic effect of Lthreo3,4dihydroxyphenylserine, a noradrenaline precursor, in rats and mice.","volume":"38","author":"Katsube","year":"1986","journal-title":"J Pharm Pharmacol"},{"key":"R18-29-20241202","doi-asserted-by":"crossref","first-page":"431439","DOI":"10.1016\/S0021-5198(19)40036-X","article-title":"Diuretic effects of Lthreo3,4dihydroxyphenylserine (LthreoDOPS) in anesthetized rats.","volume":"52","author":"Morimoto","year":"1990","journal-title":"Jpn J Pharmacol"},{"key":"R19-29-20241202","doi-asserted-by":"crossref","first-page":"363368","DOI":"10.1007\/s10286-004-0221-z","article-title":"Clinical pharmacokinetics of the norepinephrine precursor LthreoDOPS in primary chronic autonomic failure.","volume":"14","author":"Goldstein","year":"2004","journal-title":"Clin Auton Res"},{"key":"R20-29-20241202","doi-asserted-by":"crossref","first-page":"84678477","DOI":"10.1128\/MCB.22.24.8467-8477.2002","article-title":"Rho GTPaseRho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase BAkt in human endothelial cells.","volume":"22","author":"Ming","year":"2002","journal-title":"Mol Cell Biol"},{"key":"R21-29-20241202","doi-asserted-by":"crossref","first-page":"242253","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoARhokinase and activation of endothelial nitric oxide synthase.","volume":"46","author":"Trebicka","year":"2007","journal-title":"Hepatology"},{"key":"R22-29-20241202","doi-asserted-by":"crossref","first-page":"493503","DOI":"10.1111\/j.1472-8206.1996.tb00606.x","article-title":"Alphaadrenergic regulation of human renal function.","volume":"10","author":"Michel","year":"1996","journal-title":"Fundam Clin Pharmacol"},{"key":"R24-29-20241202","doi-asserted-by":"crossref","first-page":"111119","DOI":"10.1053\/j.gastro.2007.10.055","article-title":"Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis.","volume":"134","author":"Stadlbauer","year":"2008","journal-title":"Gastroenterology"},{"key":"R25-29-20241202","first-page":"611617","article-title":"Haemodynamic and renal evolution of the bile ductligated rat.","volume":"98","author":"MartinezPrieto","year":"2000","journal-title":"Clin Sci (Lond)"},{"key":"R26-29-20241202","doi-asserted-by":"crossref","first-page":"45054511","DOI":"10.3748\/wjg.14.4505","article-title":"Development of hepatorenal syndrome in bile duct ligated rats.","volume":"14","author":"Pereira","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R27-29-20241202","doi-asserted-by":"crossref","first-page":"314321","DOI":"10.1002\/hep.1840120220","article-title":"Norepinephrineinduced cholestasis in the isolated perfused rat liver is secondary to its hemodynamic effects.","volume":"12","author":"Lenzen","year":"1990","journal-title":"Hepatology"},{"key":"R28-29-20241202","doi-asserted-by":"crossref","first-page":"438445","DOI":"10.1136\/gut.2003.026658","article-title":"Hepatic fibrogenesis requires sympathetic neurotransmitters.","volume":"53","author":"Oben","year":"2004","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.25845","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201211000-00029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:03:48Z","timestamp":1733155428000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201211000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.25845","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}